Seoul, South Korea

Jae-Kyun Lee


Average Co-Inventor Count = 31.9

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jae-Kyun Lee: Innovator in Neurodegenerative Disease Treatment

Introduction

Jae-Kyun Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of neurodegenerative diseases through his innovative research and patent developments. His work focuses on creating novel compounds that can aid in the prevention and treatment of various brain diseases.

Latest Patents

Jae-Kyun Lee holds a patent for "Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same." This patent presents novel benzoarylureido compounds that are designed for the prevention and treatment of neurodegenerative brain diseases, including Alzheimer's disease, dementia, Parkinson's disease, stroke, amyloidosis, Pick's disease, Lou Gehrig's disease, Huntington's disease, and Creutzfeldt-Jakob disease. His innovative approach aims to provide new therapeutic options for these debilitating conditions.

Career Highlights

Jae-Kyun Lee is affiliated with the Korea Institute of Science and Technology, where he conducts his research. His work has garnered attention for its potential impact on the treatment of neurodegenerative diseases. With a focus on scientific advancement, he continues to explore new avenues for medical innovation.

Collaborations

Throughout his career, Jae-Kyun Lee has collaborated with esteemed colleagues, including Hoh-Gyu Hahn and Kee-Dal Nam. These partnerships have fostered a collaborative environment that enhances the research and development of effective treatments for neurodegenerative diseases.

Conclusion

Jae-Kyun Lee's contributions to the field of neurodegenerative disease treatment through his innovative patents and research are noteworthy. His work holds promise for improving the lives of those affected by these challenging conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…